Announcement PDF Market Announcement 3 June 2026 3 June 2026 Market Announcement 1/1 ASX Limited ASX Customer Service Centre 131 279 | asx.com.au #11093369v1 Microba Life Sciences Limited (ASX: MAP) – Trading Halt Trading in the securities of Microba Life Sciences Limited (‘MAP’) will be halted at the request of MAP, pending the release of an announcement by MAP. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Friday, 5 June 2026; or • the release of the announcement to the market. MAP’s request for a trading halt is attached below for the information of the market. Issued by ASX Compliance ASX Announcement 3 June 2026 JOIN MICROBA’S INTERACTIVE INVESTOR HUB For more Company information and to engage with management by asking questions about Microba’s latest announcements and updates, visit ir.microba.com/welcome Microba Life Sciences Ltd | ABN 82 617 096 652 | L10, 324 Queen Street, Brisbane QLD 4000 Australia | 1300 974 621 Ms Renee Hutchens Adviser, ASX Listings Compliance (Sydney) 20 Bridge Street, SYDNEY, NSW 2000 By email: tradinghaltssydney@asx.com.au Request for a Trading Halt – Microba Life Sciences Ltd (ASX: MAP) Microba Life Sciences Ltd (ASX: MAP) (Microba), requests an immediate trading halt be granted by ASX Limited in respect of its shares on Wednesday, 3 June 2026. The trading halt is requested in relation to a material capital raise and update on Microba's path to break even (Capital Raise and Break Even Update). In accordance with ASX Listing Rule 17.1, Microba provides the following information: (a) the trading halt is necessary for Microba to make an announcement to the market in relation to the Capital Raise and Break Even Update; (b) the trading halt should remain in place until the earlier of the commencement of trading on Friday, 5 June 2026 or such time that Microba makes an announcement to the market in relation to the Capital Raise and Break Even Update; (c) Microba is not aware of any reason why the trading halt should not be granted; and (d) Microba is not aware of any other information necessary to inform the market about the trading halt. Yours sincerely, James Heath CFO & Company Secretary This announcement has been authorised for release by the Board of Directors. For further information, please contact: Dr Luke Reid Chief Executive Officer luke.reid@microba.com Investor / Media Relations investor@microba.com https://ir.microba.com/welcome About Microba Life Sciences Limited Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com